227 related articles for article (PubMed ID: 38611041)
1. Biomarkers for Pre-Treatment Risk Stratification of Prostate Cancer Patients: A Systematic Review.
Sequeira JP; Salta S; Freitas R; López-López R; Díaz-Lagares Á; Henrique R; Jerónimo C
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38611041
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score.
Van Neste L; Hendriks RJ; Dijkstra S; Trooskens G; Cornel EB; Jannink SA; de Jong H; Hessels D; Smit FP; Melchers WJ; Leyten GH; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; Hulsbergen-van de Kaa CA; Mulders PF; van Oort IM; Van Criekinge W; Schalken JA
Eur Urol; 2016 Nov; 70(5):740-748. PubMed ID: 27108162
[TBL] [Abstract][Full Text] [Related]
4. Establishing a Urine-Based Biomarker Assay for Prostate Cancer Risk Stratification.
Guo J; Liu D; Zhang X; Johnson H; Feng X; Zhang H; Wu AHB; Chen L; Fang J; Xiao Z; Xiao K; Persson JL; Zou C
Front Cell Dev Biol; 2020; 8():597961. PubMed ID: 33363151
[TBL] [Abstract][Full Text] [Related]
5. Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions.
Hendriks RJ; van Oort IM; Schalken JA
Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):12-19. PubMed ID: 27922627
[TBL] [Abstract][Full Text] [Related]
6. Urinary Prostate Cancer Antigen 3 as a Tumour Marker: Biochemical and Clinical Aspects.
Schmid M; Hansen J; Chun FK
Adv Exp Med Biol; 2015; 867():277-89. PubMed ID: 26530372
[TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
8. Genomic Markers in Prostate Cancer Decision Making.
Cucchiara V; Cooperberg MR; Dall'Era M; Lin DW; Montorsi F; Schalken JA; Evans CP
Eur Urol; 2018 Apr; 73(4):572-582. PubMed ID: 29129398
[TBL] [Abstract][Full Text] [Related]
9. The Impact of Positron Emission Tomography Imaging and Tumor Molecular Profiling on Risk Stratification, Treatment Choice, and Oncological Outcomes of Patients with Primary or Relapsed Prostate Cancer: An International Collaborative Review of the Existing Literature.
Sood A; Kishan AU; Evans CP; Feng FY; Morgan TM; Murphy DG; Padhani AR; Pinto P; Van der Poel HG; Tilki D; Briganti A; Abdollah F
Eur Urol Oncol; 2024 Feb; 7(1):27-43. PubMed ID: 37423774
[TBL] [Abstract][Full Text] [Related]
10. The potential of cell-free and exosomal microRNAs as biomarkers in liquid biopsy in patients with prostate cancer.
de Nóbrega M; Dos Reis MB; Pereira ÉR; de Souza MF; de Syllos Cólus IM
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2893-2910. PubMed ID: 35922694
[TBL] [Abstract][Full Text] [Related]
11. A European Model for an Organised Risk-stratified Early Detection Programme for Prostate Cancer.
Van Poppel H; Hogenhout R; Albers P; van den Bergh RCN; Barentsz JO; Roobol MJ
Eur Urol Oncol; 2021 Oct; 4(5):731-739. PubMed ID: 34364829
[TBL] [Abstract][Full Text] [Related]
12. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
[TBL] [Abstract][Full Text] [Related]
13. Screening for prostate cancer.
Ilic D; Neuberger MM; Djulbegovic M; Dahm P
Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD004720. PubMed ID: 23440794
[TBL] [Abstract][Full Text] [Related]
14. A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer.
Zhao F; Olkhov-Mitsel E; Kamdar S; Jeyapala R; Garcia J; Hurst R; Hanna MY; Mills R; Tuzova AV; O'Reilly E; Kelly S; Cooper C; ; Brewer D; Perry AS; Clark J; Fleshner N; Bapat B
Clin Epigenetics; 2018 Nov; 10(1):147. PubMed ID: 30470249
[TBL] [Abstract][Full Text] [Related]
15. Prostate-Specific Antigen (PSA) Screening and New Biomarkers for Prostate Cancer (PCa).
Stephan C; Rittenhouse H; Hu X; Cammann H; Jung K
EJIFCC; 2014 Apr; 25(1):55-78. PubMed ID: 27683457
[TBL] [Abstract][Full Text] [Related]
16. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
[TBL] [Abstract][Full Text] [Related]
17. The role of biomarkers in the assessment of prostate cancer risk prior to prostate biopsy: which markers matter and how should they be used?
Schmid M; Trinh QD; Graefen M; Fisch M; Chun FK; Hansen J
World J Urol; 2014 Aug; 32(4):871-80. PubMed ID: 24825472
[TBL] [Abstract][Full Text] [Related]
18. Liquid Biopsy Potential Biomarkers in Prostate Cancer.
Neuhaus J; Yang B
Diagnostics (Basel); 2018 Sep; 8(4):. PubMed ID: 30698162
[TBL] [Abstract][Full Text] [Related]
19. Variability in Outcomes for Patients with Intermediate-risk Prostate Cancer (Gleason Score 7, International Society of Urological Pathology Gleason Group 2-3) and Implications for Risk Stratification: A Systematic Review.
Kane CJ; Eggener SE; Shindel AW; Andriole GL
Eur Urol Focus; 2017 Oct; 3(4-5):487-497. PubMed ID: 28753804
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
